A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

被引：0
|
作者：
Takeo Fujii
Hiroko Masuda
Yee Chung Cheng
Fei Yang
Aysegul A. Sahin
Yasuto Naoi
Yuki Matsunaga
Akshara Raghavendra
Arup Kumar Sinha
Jose Rodrigo Espinosa Fernandez
Anjali James
Keisuke Yamagishi
Tomoko Matsushima
Robert Schuetz
Debu Tripathy
Sachiyo Tada
Rubie S. Jackson
Shinzaburo Noguchi
Seigo Nakamura
Jared D. Acoba
Naoto T. Ueno
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Breast Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354
[3] University of Hawai’i,John A. Burns School of Medicine
[4] University of Hawai’i Cancer Center,Department of Breast Surgical Oncology
[5] Showa University,Division of Hematology and Oncology
[6] Medical College of Wisconsin,Department of Translational Molecular Pathology
[7] The University of Texas MD Anderson Cancer Center,Department of Pathology
[8] The University of Texas MD Anderson Cancer Center,Department of Breast and Endocrine Surgery
[9] Osaka University Graduate School of Medicine,Anne Arundel Medical Center
[10] Sysmex Corporation,undefined
[11] Rebecca Fortney Breast Center,undefined
[12] Hyogo Prefectural Nishinomiya Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive; Recurrence Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：455 / 461
页数：6
相关论文
共 50 条
  • [31] Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage
    Yang Yu-qing
    Wang Lei
    Huang Mei-ling
    Xiao Jing-jing
    Wei Mei-chen
    Wu Jiang
    Hao Jun-sheng
    Ling Rui
    Li Nan-lin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 150 - 155
  • [32] Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
    Kim, Yun Yeong
    Oh, Se Jeong
    Chun, Yong Soon
    Lee, Woon Kee
    Park, Heung Kyu
    PLOS ONE, 2018, 13 (07):
  • [33] Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Gong Tang
    Steven Shak
    Soonmyung Paik
    Stewart J. Anderson
    Joseph P. Costantino
    Charles E. Geyer
    Eleftherios P. Mamounas
    D. Lawrence Wickerham
    Norman Wolmark
    Breast Cancer Research and Treatment, 2011, 127 : 133 - 142
  • [34] 21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
    Zhang, Wen-Wen
    Tong, Qin
    Sun, Jia-Yuan
    Hua, Xin
    Long, Zhi-Qing
    Deng, Jia-Peng
    Dong, Yong
    Li, Fang-Yan
    He, Zhen-Yu
    Wu, San-Gang
    Lin, Huan-Xin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [35] Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Tang, Gong
    Shak, Steven
    Paik, Soonmyung
    Anderson, Stewart J.
    Costantino, Joseph P.
    Geyer, Charles E., Jr.
    Mamounas, Eleftherios P.
    Wickerham, D. Lawrence
    Wolmark, Norman
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (01) : 133 - 142
  • [36] Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score
    Ahn, Sung Gwe
    Lee, Hak Min
    Lee, Hak Woo
    Lee, Seung Ah
    Lee, Se-Ra
    Leem, Sun-Hee
    Jeong, Joon
    Chu, In-Sun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (12) : 23685 - 23699
  • [37] 21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
    Zhu, Yifei
    Wang, Tiange
    Tong, Yiwei
    Chen, Xiaosong
    Shen, Kunwei
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [38] Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
    Pelaez-Garcia, Alberto
    Yebenes, Laura
    Berjon, Alberto
    Angulo, Antonia
    Zamora, Pilar
    Sanchez-Mendez, Jose Ignacio
    Espinosa, Enrique
    Redondo, Andres
    Heredia-Soto, Victoria
    Mendiola, Marta
    Feliu, Jaime
    Hardisson, David
    PLOS ONE, 2017, 12 (09):
  • [39] First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Giarratano, Tommaso
    Mion, Marta
    Tortora, Giampaolo
    De Rossi, Costanza
    Gori, Stefania
    Oliani, Cristina
    Merlini, Laura
    Pasini, Felice
    Bonciarelli, Giorgio
    Griguolo, Gaia
    Orvieto, Enrico
    Michieletto, Silvia
    Saibene, Tania
    Del Bianco, Paola
    De Salvo, Gian Luca
    Conte, PierFranco
    ONCOLOGIST, 2018, 23 (03) : 297 - 305
  • [40] Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer
    Breaux, Andrea
    Turner, Bradley
    Wu, Xiaoyong
    Rai, Shesh N.
    Riley, Elizabeth C.
    Mandadi, Mounika
    Sanders, Mary Ann
    CLINICAL BREAST CANCER, 2019, 19 (01) : E261 - E269
12345